Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial

C. Pacilio, A. Morabito, F. Nuzzo, A. Gravina, V. Labonia, G. Landi, E. Rossi, E. De Maio, M. Di Maio, G. D'Aiuto, G. Botti, N. Normanno, P. Chiodini, C. Gallo, F. Perrone, A. De Matteis

Research output: Contribution to journalArticle

Abstract

The aim of the study was to demonstrate the superiority of docetaxel and epirubicin vs docetaxel alone as first-line therapy in metastatic breast cancer patients pretreated with adjuvant or neoadjuvant epirubicin. We compared single agent docetaxel 100 mg m-2 (D) with the combination of docetaxel 80 mg m-2 and epirubicin 75 mg m-2 (ED). The response rate (72 vs 79%), the progression-free survival (median 9 vs 11 months) and the overall survival (median 18 vs 21 months) were not significantly different between the ED (n = 26) and D arms (n = 25), respectively. Leucopaenia, nausea and stomatitis were significantly worse with ED. In conclusion, epirubicin should not be administered in combination with taxanes in metastatic breast cancer patients relapsed after an anthracycline-based adjuvant or neoadjuvant therapy.

Original languageEnglish
Pages (from-to)1233-1236
Number of pages4
JournalBritish Journal of Cancer
Volume94
Issue number9
DOIs
Publication statusPublished - May 8 2006

Keywords

  • Adjuvant anthracyclines
  • Docetaxel
  • Epirubicin
  • Metastatic breast cancer
  • Randomised trials

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial'. Together they form a unique fingerprint.

  • Cite this